The link, located here is an interview with Reiner Fuellmich, a lawyer (a good one) that’s been at the center of the ‘speck’ investigation since inception.
This one interview, all nineteen-minutes, thirty one seconds, is probably the best summary of the current situation.
The link above comes with a warning:
If you’re one of those still asleep, after watching the interview, you’ll never be the same. You’ll be forever changed.
To put it biblically, “Your eyes will be opened”.
That is, if this lie can be perpetrated world-wide (as it has), then what does that say about all other media generated propaganda: the (stolen) election, the fake oval office, the fake executive orders, the fake insurrection.
The examples above are just from the past six-months!
For emphasis, we’ll throw in one more link that seems un-related but it’s not; it shows just how long events have been purposely shaped to fit a narrative.
Of course, this ‘thought shaping’ goes back even farther … if not a hundred years or more.
So, what’s all this have to do with the markets and specifically biotech, IBB?
The interview’s implications for biotech are clear.
David Stockman has a post located here whose title sums it up nicely:
‘… a scam like no other’.
It’s just a matter of time before the public is either awakened or severely, permanently, damaged by following (and believing) the lie.
This time around, cemeteries are likely to be overrun … for real.
If that happens, repercussions to the biotech sector would (likely) be severe to catastrophic (down -90%, maybe?).
Even though a few within IBB are directly involved, all are likely to take a hit
In our Project Stimulus table, we’re short biotech via LABD (not advice, not a recommendation). The stop has been moved above break-even.
It’s important to not let fundamentals (above) bleed into market positioning. It’s impossible to say when or if fundamentals will take control.
What we have now is IBB looking as if those fundamentals are providing a backdrop for technical action (described below). However, technical action can change instantly.
Biotech, IBB Technical Analysis:
Typically, this morning’s action would signal a ‘short exit’ or ‘go long’; when price action immediately gaps above the prior session high.
However, we already know on a long term (quarterly, monthly, weekly) basis, IBB has reversed. That does not mean price can’t go into some type of truncated rally … it can.
What the long term momentum says, if a rally occurs, it’s likely to be short and reverse quickly.
As of this post, it looks like whatever rally there was, it was over within the hour.
DRV pushed through our stop early in the session; position closed (not advice, not a recommendation).
1:50 p.m. EST:
Despite all the analysis, IYR is showing continued buoyancy.
Something else is going on; possibly related to Uneducated Economist’s link provided in the last update.
Taking his cue, a functioning mortgage market is all important to the financial narrative, it’s possible this market will be more heavily manipulated than others.
At this juncture it would make sense. All indications are for reversal … yet it’s not happening in any significant way.
Time for another trade.
We’re going back to a market that in retrospect, should’ve been the focus all along; Biotech.
This site’s coming from the perspective those reading, are well aware the ‘speck’ as we call it (to avoid censorship) was a fabricated event.
Just a reminder that we’re not some ‘Johnny come lately’, here’s the link from way back in May, last year.
That post proves the situation was figured out well before the May 17th publish date (interviews, observations conducted a month prior).
What’s not fabricated however, are the repercussions from the so-called cure for the speck.
Unfortunately, those are happening now and are quite real.
Moving on to the trade.
Despite the number of transactions shown in the Project Stimulus table (below), the objective is to minimize activity. We’re looking for a mid, to long term sustainable move; gain potential, 100% to 1,000%.